Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,27518170,Cmax,"For atomoxetine, Cmax increased from 226±96.1 to 386±137 ng/mL and more importantly, AUC0-∞ was significantly increasedfrom 1580±1040 to 8060±4160 ng*h/mL, while the mean t1/2 was prolonged after bupropion pretreatment.",Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27518170/),[ng] / [ml],226,12854,DB00289,Atomoxetine
,27518170,Cmax,"For atomoxetine, Cmax increased from 226±96.1 to 386±137 ng/mL and more importantly, AUC0-∞ was significantly increasedfrom 1580±1040 to 8060±4160 ng*h/mL, while the mean t1/2 was prolonged after bupropion pretreatment.",Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27518170/),[ng] / [ml],386,12855,DB00289,Atomoxetine
,27518170,AUC0-∞,"For atomoxetine, Cmax increased from 226±96.1 to 386±137 ng/mL and more importantly, AUC0-∞ was significantly increasedfrom 1580±1040 to 8060±4160 ng*h/mL, while the mean t1/2 was prolonged after bupropion pretreatment.",Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27518170/),[h·ng] / [ml],1580,12856,DB00289,Atomoxetine
,27518170,AUC0-∞,"For atomoxetine, Cmax increased from 226±96.1 to 386±137 ng/mL and more importantly, AUC0-∞ was significantly increasedfrom 1580±1040 to 8060±4160 ng*h/mL, while the mean t1/2 was prolonged after bupropion pretreatment.",Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27518170/),[h·ng] / [ml],8060,12857,DB00289,Atomoxetine
,27518170,Cmax,"For 4-hydroxyatomoxetine-O-glucuronide, Cmax and AUC0-∞ were decreased from 707±269 to 212±145 ng/mL and from 5750±1240 to 3860±1220 ng*h/mL, respectively.",Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27518170/),[ng] / [ml],707,12858,DB00289,Atomoxetine
,27518170,AUC0-∞,"For 4-hydroxyatomoxetine-O-glucuronide, Cmax and AUC0-∞ were decreased from 707±269 to 212±145 ng/mL and from 5750±1240 to 3860±1220 ng*h/mL, respectively.",Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27518170/),[ng] / [ml],212,12859,DB00289,Atomoxetine
,27518170,AUC0-∞,"For 4-hydroxyatomoxetine-O-glucuronide, Cmax and AUC0-∞ were decreased from 707±269 to 212±145 ng/mL and from 5750±1240 to 3860±1220 ng*h/mL, respectively.",Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27518170/),[h·ng] / [ml],5750,12860,DB00289,Atomoxetine
,27518170,AUC0-∞,"For 4-hydroxyatomoxetine-O-glucuronide, Cmax and AUC0-∞ were decreased from 707±269 to 212±145 ng/mL and from 5750±1240 to 3860±1220 ng*h/mL, respectively.",Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27518170/),[h·ng] / [ml],3860,12861,DB00289,Atomoxetine
,15788540,kinact,"We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.",In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),1/[min],0.17,28928,DB00289,Atomoxetine
,15788540,unbound KI,"We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.",In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),μM,0.315,28929,DB00289,Atomoxetine
,15788540,degradation half-life,"We have predicted the pharmacokinetic consequences of CYP2D6 inactivation by paroxetine from in vitro inactivation kinetics (kinact 0.17 min(-1), unbound KI 0.315 microM), in vivo inhibitor concentrations, and an estimated CYP2D6 degradation half-life of 51 h, using a mathematical model of mechanism-based inhibition.",In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),h,51,28930,DB00289,Atomoxetine
,15788540,degradation half-life,Simulation of the sensitivities of these predictions to model inputs suggests a 2-fold underprediction of interaction magnitude when a CYP2D6 degradation half-life of 14 h (reported for rat CYP3A) is used.,In vitro-in vivo extrapolation of CYP2D6 inactivation by paroxetine: prediction of nonstationary pharmacokinetics and drug interaction magnitude. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15788540/),h,14,28931,DB00289,Atomoxetine
,27816979,AUC,"Small, but statistically significant increases in AUC values were reported for both parent drug (1,583.05 ± 1,040.29 vs. 2,111.55 ± 1,411.59 ng*h/ml) and 4-hydroxyatomoxetine-O-glucuronide (5,754.71 ± 1,235.5 vs. 6,293.17 ± 1,219.34 ng*h/ml) after combined treatment of ATX and the enzymatic inhibitor.",Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27816979/),[h·ng] / [ml],"1,583.05",29235,DB00289,Atomoxetine
,27816979,AUC,"Small, but statistically significant increases in AUC values were reported for both parent drug (1,583.05 ± 1,040.29 vs. 2,111.55 ± 1,411.59 ng*h/ml) and 4-hydroxyatomoxetine-O-glucuronide (5,754.71 ± 1,235.5 vs. 6,293.17 ± 1,219.34 ng*h/ml) after combined treatment of ATX and the enzymatic inhibitor.",Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27816979/),[h·ng] / [ml],"2,111.55",29236,DB00289,Atomoxetine
,27816979,AUC,"Small, but statistically significant increases in AUC values were reported for both parent drug (1,583.05 ± 1,040.29 vs. 2,111.55 ± 1,411.59 ng*h/ml) and 4-hydroxyatomoxetine-O-glucuronide (5,754.71 ± 1,235.5 vs. 6,293.17 ± 1,219.34 ng*h/ml) after combined treatment of ATX and the enzymatic inhibitor.",Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27816979/),[h·ng] / [ml],"5,754.71",29237,DB00289,Atomoxetine
,27816979,AUC,"Small, but statistically significant increases in AUC values were reported for both parent drug (1,583.05 ± 1,040.29 vs. 2,111.55 ± 1,411.59 ng*h/ml) and 4-hydroxyatomoxetine-O-glucuronide (5,754.71 ± 1,235.5 vs. 6,293.17 ± 1,219.34 ng*h/ml) after combined treatment of ATX and the enzymatic inhibitor.",Evaluation of the Potential Pharmacokinetic Interaction between Atomoxetine and Fluvoxamine in Healthy Volunteers. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27816979/),[h·ng] / [ml],"6,293.17",29238,DB00289,Atomoxetine
,27474159,plasma concentrations,"The plasma concentrations were 53.2 ± 67.0, 298.0 ± 390.5, and 639.3 ± 831.9 ng/mL at doses of 40 mg, 80 mg, and 120 mg, and the concentration/dose were 1.33 ± 1.67, 3.73 ± 4.88, and 5.33 ± 6.93 ng/mL/mg, respectively.",Non-Linear Pharmacokinetics of Atomoxetine in Adult Japanese Patients With ADHD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474159/),[ng] / [ml],53.2,37077,DB00289,Atomoxetine
,27474159,plasma concentrations,"The plasma concentrations were 53.2 ± 67.0, 298.0 ± 390.5, and 639.3 ± 831.9 ng/mL at doses of 40 mg, 80 mg, and 120 mg, and the concentration/dose were 1.33 ± 1.67, 3.73 ± 4.88, and 5.33 ± 6.93 ng/mL/mg, respectively.",Non-Linear Pharmacokinetics of Atomoxetine in Adult Japanese Patients With ADHD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474159/),[ng] / [ml],298.0,37078,DB00289,Atomoxetine
,27474159,plasma concentrations,"The plasma concentrations were 53.2 ± 67.0, 298.0 ± 390.5, and 639.3 ± 831.9 ng/mL at doses of 40 mg, 80 mg, and 120 mg, and the concentration/dose were 1.33 ± 1.67, 3.73 ± 4.88, and 5.33 ± 6.93 ng/mL/mg, respectively.",Non-Linear Pharmacokinetics of Atomoxetine in Adult Japanese Patients With ADHD. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474159/),[ng] / [ml],639.3,37079,DB00289,Atomoxetine
,27474159,concentration/dose,"The plasma concentrations were 53.2 ± 67.0, 298.0 ± 390.5, and 639.3 ± 831.9 ng/mL at doses of 40 mg, 80 mg, and 120 mg, and the concentration/dose were 1.33 ± 1.67, 3.73 ± 4.88, and 5.33 ± 6.93 ng/mL/mg, respectively.",Non-Linear Pharmacokinetics of Atomoxetine in Adult Japanese Patients With ADHD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474159/),[ng] / [mg·ml],1.33,37080,DB00289,Atomoxetine
,27474159,concentration/dose,"The plasma concentrations were 53.2 ± 67.0, 298.0 ± 390.5, and 639.3 ± 831.9 ng/mL at doses of 40 mg, 80 mg, and 120 mg, and the concentration/dose were 1.33 ± 1.67, 3.73 ± 4.88, and 5.33 ± 6.93 ng/mL/mg, respectively.",Non-Linear Pharmacokinetics of Atomoxetine in Adult Japanese Patients With ADHD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474159/),[ng] / [mg·ml],3.73,37081,DB00289,Atomoxetine
,27474159,concentration/dose,"The plasma concentrations were 53.2 ± 67.0, 298.0 ± 390.5, and 639.3 ± 831.9 ng/mL at doses of 40 mg, 80 mg, and 120 mg, and the concentration/dose were 1.33 ± 1.67, 3.73 ± 4.88, and 5.33 ± 6.93 ng/mL/mg, respectively.",Non-Linear Pharmacokinetics of Atomoxetine in Adult Japanese Patients With ADHD. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27474159/),[ng] / [mg·ml],5.33,37082,DB00289,Atomoxetine
,12804126,Half-life,"Half-life averaged 3.12 and 3.28 hours after a single dose and at steady state, respectively.",Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12804126/),h,3.12,40730,DB00289,Atomoxetine
,12804126,Half-life,"Half-life averaged 3.12 and 3.28 hours after a single dose and at steady state, respectively.",Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12804126/),h,3.28,40731,DB00289,Atomoxetine
,19722525,IC(50),"Numerous compounds (e.g., 19-22) had low nonamolar hNET potency with IC(50) values of 7-10 nM and excellent selectivity (>500 fold) at hNET over hSERT and hDAT.","1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2H-benzimidazol-2-ones: potent, selective, and orally efficacious norepinephrine reuptake inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19722525/),nM,7-10,56724,DB00289,Atomoxetine
,27207674,IC50,"Moreover, myricetin showed inhibitory effect on human and rat microsomes, the IC50 of myricetin was 8.651 and 35.45 µmol/L, respectively.",The Effect of Myricetin on Pharmacokinetics of Atomoxetine and its Metabolite 4-Hydroxyatomoxetine In Vivo and In Vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207674/),[μM] / [l],8.651,74285,DB00289,Atomoxetine
,27207674,IC50,"Moreover, myricetin showed inhibitory effect on human and rat microsomes, the IC50 of myricetin was 8.651 and 35.45 µmol/L, respectively.",The Effect of Myricetin on Pharmacokinetics of Atomoxetine and its Metabolite 4-Hydroxyatomoxetine In Vivo and In Vitro. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27207674/),[μM] / [l],35.45,74286,DB00289,Atomoxetine
,18936112,C(B)/C(ECF),"On the basis of the ratios of whole brain concentration to C(ECF) (C(B)/C(ECF)=170), brain cell (BC) concentration to C(ECF) (C(BC)/C(ECF)=219), and unbound brain cell concentration to C(ECF) (C(uBC)/C(ECF)=2.9), we conclude that whole brain concentration does not represent the concentration in the biophase and atomoxetine primarily partitions into brain cells.",Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18936112/),,170,74772,DB00289,Atomoxetine
,18936112,C(BC)/C(ECF),"On the basis of the ratios of whole brain concentration to C(ECF) (C(B)/C(ECF)=170), brain cell (BC) concentration to C(ECF) (C(BC)/C(ECF)=219), and unbound brain cell concentration to C(ECF) (C(uBC)/C(ECF)=2.9), we conclude that whole brain concentration does not represent the concentration in the biophase and atomoxetine primarily partitions into brain cells.",Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18936112/),,219,74773,DB00289,Atomoxetine
,18936112,C(uBC)/C(ECF),"On the basis of the ratios of whole brain concentration to C(ECF) (C(B)/C(ECF)=170), brain cell (BC) concentration to C(ECF) (C(BC)/C(ECF)=219), and unbound brain cell concentration to C(ECF) (C(uBC)/C(ECF)=2.9), we conclude that whole brain concentration does not represent the concentration in the biophase and atomoxetine primarily partitions into brain cells.",Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18936112/),,2.9,74774,DB00289,Atomoxetine
,18936112,Q(BBB),The distributional clearance at the BBB (Q(BBB)=0.00110 l/h) was estimated to be 12 times more rapid than that at the BCB (Q(BCB)=0.0000909 l/h) and similar to the clearances across brain parenchyma (CL(ECF-BC)=0.00216 l/h; CL(BC-ECF)=0.000934 l/h).,Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18936112/),[l] / [h],0.00110,74775,DB00289,Atomoxetine
,18936112,Q(BCB),The distributional clearance at the BBB (Q(BBB)=0.00110 l/h) was estimated to be 12 times more rapid than that at the BCB (Q(BCB)=0.0000909 l/h) and similar to the clearances across brain parenchyma (CL(ECF-BC)=0.00216 l/h; CL(BC-ECF)=0.000934 l/h).,Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18936112/),[l] / [h],0.0000909,74776,DB00289,Atomoxetine
,18936112,CL(ECF-BC),The distributional clearance at the BBB (Q(BBB)=0.00110 l/h) was estimated to be 12 times more rapid than that at the BCB (Q(BCB)=0.0000909 l/h) and similar to the clearances across brain parenchyma (CL(ECF-BC)=0.00216 l/h; CL(BC-ECF)=0.000934 l/h).,Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18936112/),[l] / [h],0.00216,74777,DB00289,Atomoxetine
,18936112,CL(BC-ECF),The distributional clearance at the BBB (Q(BBB)=0.00110 l/h) was estimated to be 12 times more rapid than that at the BCB (Q(BCB)=0.0000909 l/h) and similar to the clearances across brain parenchyma (CL(ECF-BC)=0.00216 l/h; CL(BC-ECF)=0.000934 l/h).,Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18936112/),[l] / [h],0.000934,74778,DB00289,Atomoxetine
,26733750,Cmax,"Cmax increased from 221.26±94.93 to 372.53±128.28 ng/mL, while AUC0-t and AUC0-∞ also increased from 1151.19±686.52 to 6452.37±3388.76 ng*h/mL, and from 1229.15±751.04 to 7111.74±4195.17 ng*h/mL respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[ng] / [ml],221.26,81021,DB00289,Atomoxetine
,26733750,Cmax,"Cmax increased from 221.26±94.93 to 372.53±128.28 ng/mL, while AUC0-t and AUC0-∞ also increased from 1151.19±686.52 to 6452.37±3388.76 ng*h/mL, and from 1229.15±751.04 to 7111.74±4195.17 ng*h/mL respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[ng] / [ml],372.53,81022,DB00289,Atomoxetine
,26733750,AUC0-t,"Cmax increased from 221.26±94.93 to 372.53±128.28 ng/mL, while AUC0-t and AUC0-∞ also increased from 1151.19±686.52 to 6452.37±3388.76 ng*h/mL, and from 1229.15±751.04 to 7111.74±4195.17 ng*h/mL respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],1151.19,81023,DB00289,Atomoxetine
,26733750,AUC0-∞,"Cmax increased from 221.26±94.93 to 372.53±128.28 ng/mL, while AUC0-t and AUC0-∞ also increased from 1151.19±686.52 to 6452.37±3388.76 ng*h/mL, and from 1229.15±751.04 to 7111.74±4195.17 ng*h/mL respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],6452.37,81024,DB00289,Atomoxetine
,26733750,AUC0-∞,"Cmax increased from 221.26±94.93 to 372.53±128.28 ng/mL, while AUC0-t and AUC0-∞ also increased from 1151.19±686.52 to 6452.37±3388.76 ng*h/mL, and from 1229.15±751.04 to 7111.74±4195.17 ng*h/mL respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],1229.15,81025,DB00289,Atomoxetine
,26733750,AUC0-∞,"Cmax increased from 221.26±94.93 to 372.53±128.28 ng/mL, while AUC0-t and AUC0-∞ also increased from 1151.19±686.52 to 6452.37±3388.76 ng*h/mL, and from 1229.15±751.04 to 7111.74±4195.17 ng*h/mL respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],7111.74,81026,DB00289,Atomoxetine
,26733750,Cmax,"The main metabolite pharmacokinetics was also influenced by paroxetine intake, namely Cmax, AUC0-t and AUC0-∞ decreased from 688.76±270.27 to 131.01±100.43 ng*h/mL, and from 4810.93±845.06 to 2606.04±923.88 and from 4928.55±853.25 to 3029.82 ±941.84 respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],688.76,81027,DB00289,Atomoxetine
,26733750,AUC0-t,"The main metabolite pharmacokinetics was also influenced by paroxetine intake, namely Cmax, AUC0-t and AUC0-∞ decreased from 688.76±270.27 to 131.01±100.43 ng*h/mL, and from 4810.93±845.06 to 2606.04±923.88 and from 4928.55±853.25 to 3029.82 ±941.84 respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],131.01,81028,DB00289,Atomoxetine
,26733750,AUC0-t,"The main metabolite pharmacokinetics was also influenced by paroxetine intake, namely Cmax, AUC0-t and AUC0-∞ decreased from 688.76±270.27 to 131.01±100.43 ng*h/mL, and from 4810.93±845.06 to 2606.04±923.88 and from 4928.55±853.25 to 3029.82 ±941.84 respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],4810.93,81029,DB00289,Atomoxetine
,26733750,AUC0-t,"The main metabolite pharmacokinetics was also influenced by paroxetine intake, namely Cmax, AUC0-t and AUC0-∞ decreased from 688.76±270.27 to 131.01±100.43 ng*h/mL, and from 4810.93±845.06 to 2606.04±923.88 and from 4928.55±853.25 to 3029.82 ±941.84 respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],2606.04,81030,DB00289,Atomoxetine
,26733750,AUC0-t,"The main metabolite pharmacokinetics was also influenced by paroxetine intake, namely Cmax, AUC0-t and AUC0-∞ decreased from 688.76±270.27 to 131.01±100.43 ng*h/mL, and from 4810.93±845.06 to 2606.04±923.88 and from 4928.55±853.25 to 3029.82 ±941.84 respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],4928.55,81031,DB00289,Atomoxetine
,26733750,AUC0-∞,"The main metabolite pharmacokinetics was also influenced by paroxetine intake, namely Cmax, AUC0-t and AUC0-∞ decreased from 688.76±270.27 to 131.01±100.43 ng*h/mL, and from 4810.93±845.06 to 2606.04±923.88 and from 4928.55±853.25 to 3029.82 ±941.84 respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],2606.04,81032,DB00289,Atomoxetine
,26733750,AUC0-∞,"The main metabolite pharmacokinetics was also influenced by paroxetine intake, namely Cmax, AUC0-t and AUC0-∞ decreased from 688.76±270.27 to 131.01±100.43 ng*h/mL, and from 4810.93±845.06 to 2606.04±923.88 and from 4928.55±853.25 to 3029.82 ±941.84 respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],4928.55,81033,DB00289,Atomoxetine
,26733750,AUC0-∞,"The main metabolite pharmacokinetics was also influenced by paroxetine intake, namely Cmax, AUC0-t and AUC0-∞ decreased from 688.76±270.27 to 131.01±100.43 ng*h/mL, and from 4810.93±845.06 to 2606.04±923.88 and from 4928.55±853.25 to 3029.82 ±941.84 respectively.",The influence of paroxetine on the pharmacokinetics of atomoxetine and its main metabolite. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26733750/),[h·ng] / [ml],3029.82,81034,DB00289,Atomoxetine
,4008676,plasma half-life,"Following the administration of a single 90-mg oral dose of tomoxetine to four normal volunteers, the plasma half-life was 4.3 +/- 0.5 hours.",Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008676/),h,4.3,91673,DB00289,Atomoxetine
,4008676,plasma clearance,"Mean plasma clearance was 0.60 +/- 0.14 L/Kg/hr, and the mean volume of distribution was 3.7 +/- 0.9 L/kg.",Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008676/),[l] / [h·kg],0.60,91674,DB00289,Atomoxetine
,4008676,volume of distribution,"Mean plasma clearance was 0.60 +/- 0.14 L/Kg/hr, and the mean volume of distribution was 3.7 +/- 0.9 L/kg.",Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008676/),[l] / [kg],3.7,91675,DB00289,Atomoxetine
,4008676,plasma half-life,The mean plasma half-life determined following the last dose was 4.6 +/- 0.5 hours in five subjects.,Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008676/),h,4.6,91676,DB00289,Atomoxetine
,4008676,half-life,"The other two subjects, one at each dose level, demonstrated accumulation of tomoxetine occurring from the first to last dose where tomoxetine disappeared from plasma with a mean half-life of 19 hours.",Single-dose and steady-state pharmacokinetics of tomoxetine in normal subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4008676/),h,19,91677,DB00289,Atomoxetine
,25637266,time to maximum plasma concentration,"The time to maximum plasma concentration of EDX was 2h, and the half-life was 9h.","A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637266/),h,2,96348,DB00289,Atomoxetine
,25637266,half-life,"The time to maximum plasma concentration of EDX was 2h, and the half-life was 9h.","A pharmacokinetic/pharmacodynamic investigation: assessment of edivoxetine and atomoxetine on systemic and central 3,4-dihydroxyphenylglycol, a biochemical marker for norepinephrine transporter inhibition. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25637266/),h,9,96349,DB00289,Atomoxetine
,17610534,time to maximum serum concentrations,Atomoxetine was rapidly absorbed with median time to maximum serum concentrations of approximately 1.5 h after single and multiple doses.,Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610534/),h,1.5,104376,DB00289,Atomoxetine
,17610534,apparent terminal half-life (t(1/2)),Atomoxetine concentrations appeared to decrease monoexponentially with a mean apparent terminal half-life (t(1/2)) of approximately 4 h.,Atomoxetine pharmacokinetics in healthy Chinese subjects and effect of the CYP2D6*10 allele. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17610534/),h,4,104377,DB00289,Atomoxetine
,32153037,encapsulation,"The drug encapsulation and loading efficiencies were 98.28% ± 0.59% and 0.89% ± 0.04%, respectively.",Taste masking of water-soluble drug by solid lipid microspheres: a child-friendly system established by reversed lipid-based nanoparticle technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32153037/),%,98.28,109938,DB00289,Atomoxetine
,32153037,loading efficiencies,"The drug encapsulation and loading efficiencies were 98.28% ± 0.59% and 0.89% ± 0.04%, respectively.",Taste masking of water-soluble drug by solid lipid microspheres: a child-friendly system established by reversed lipid-based nanoparticle technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32153037/),%,0.89,109939,DB00289,Atomoxetine
,22589233,tmax,4-OH-ATX was found in oral fluid at a peak concentration approximately one-fourth those in plasma with a mean tmax of 2.3 in plasma and 3.0 h in oral fluid.,Concentrations of atomoxetine and its metabolites in plasma and oral fluid from paediatric patients with attention deficit/hyperactivity disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22589233/),h,2.3,114166,DB00289,Atomoxetine
,22589233,tmax,4-OH-ATX was found in oral fluid at a peak concentration approximately one-fourth those in plasma with a mean tmax of 2.3 in plasma and 3.0 h in oral fluid.,Concentrations of atomoxetine and its metabolites in plasma and oral fluid from paediatric patients with attention deficit/hyperactivity disorder. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22589233/),h,3.0,114167,DB00289,Atomoxetine
,12485958,t(1/2),"Due to the absence of CYP2D6 activity, the systemic exposure to radioactivity was prolonged in PM subjects (t(1/2) = 62 h) compared with EM subjects (t(1/2) = 18 h).",Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485958/),h,62,123456,DB00289,Atomoxetine
,12485958,t(1/2),"Due to the absence of CYP2D6 activity, the systemic exposure to radioactivity was prolonged in PM subjects (t(1/2) = 62 h) compared with EM subjects (t(1/2) = 18 h).",Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485958/),h,18,123457,DB00289,Atomoxetine
,12485958,t(1/2),"In EM subjects, atomoxetine (t(1/2) = 5 h) and 4-hydroxyatomoxetine-O-glucuronide (t(1/2) = 7 h) were the principle circulating species, whereas atomoxetine (t(1/2) = 20 h) and N-desmethylatomoxetine (t(1/2) = 33 h) were the principle circulating species in PM subjects.",Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485958/),h,5,123458,DB00289,Atomoxetine
,12485958,t(1/2),"In EM subjects, atomoxetine (t(1/2) = 5 h) and 4-hydroxyatomoxetine-O-glucuronide (t(1/2) = 7 h) were the principle circulating species, whereas atomoxetine (t(1/2) = 20 h) and N-desmethylatomoxetine (t(1/2) = 33 h) were the principle circulating species in PM subjects.",Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485958/),h,7,123459,DB00289,Atomoxetine
,12485958,t(1/2),"In EM subjects, atomoxetine (t(1/2) = 5 h) and 4-hydroxyatomoxetine-O-glucuronide (t(1/2) = 7 h) were the principle circulating species, whereas atomoxetine (t(1/2) = 20 h) and N-desmethylatomoxetine (t(1/2) = 33 h) were the principle circulating species in PM subjects.",Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485958/),h,20,123460,DB00289,Atomoxetine
,12485958,t(1/2),"In EM subjects, atomoxetine (t(1/2) = 5 h) and 4-hydroxyatomoxetine-O-glucuronide (t(1/2) = 7 h) were the principle circulating species, whereas atomoxetine (t(1/2) = 20 h) and N-desmethylatomoxetine (t(1/2) = 33 h) were the principle circulating species in PM subjects.",Disposition and metabolic fate of atomoxetine hydrochloride: the role of CYP2D6 in human disposition and metabolism. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485958/),h,33,123461,DB00289,Atomoxetine
,15910008,Absolute oral bioavailability,"Absolute oral bioavailability ranges from 63 to 94%, which is governed by the extent of its first-pass metabolism.",Clinical pharmacokinetics of atomoxetine. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910008/),%,63 to 94,131464,DB00289,Atomoxetine
,15910008,plasma half-life,"In extensive metabolisers, atomoxetine has a plasma half-life of 5.2 hours, while in poor metabolisers, atomoxetine has a plasma half-life of 21.6 hours.",Clinical pharmacokinetics of atomoxetine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910008/),h,5.2,131465,DB00289,Atomoxetine
,15910008,plasma half-life,"In extensive metabolisers, atomoxetine has a plasma half-life of 5.2 hours, while in poor metabolisers, atomoxetine has a plasma half-life of 21.6 hours.",Clinical pharmacokinetics of atomoxetine. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910008/),h,21.6,131466,DB00289,Atomoxetine
,15910008,systemic plasma clearance,"The systemic plasma clearance of atomoxetine is 0.35 and 0.03 L/h/kg in extensive and poor metabolisers, respectively.",Clinical pharmacokinetics of atomoxetine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910008/),[l] / [h·kg],0.35,131467,DB00289,Atomoxetine
,15910008,systemic plasma clearance,"The systemic plasma clearance of atomoxetine is 0.35 and 0.03 L/h/kg in extensive and poor metabolisers, respectively.",Clinical pharmacokinetics of atomoxetine. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910008/),[l] / [h·kg],0.03,131468,DB00289,Atomoxetine
,15910008,volume of distribution,"The volume of distribution is 0.85 L/kg, indicating that atomoxetine is distributed in total body water in both extensive and poor metabolisers.",Clinical pharmacokinetics of atomoxetine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15910008/),[l] / [kg],0.85,131469,DB00289,Atomoxetine
,26660002,area under the curve [AUC]0-∞,"Dose-corrected ATX systemic exposure (area under the curve [AUC]0-∞ ) varied 29.6-fold across the study cohort, ranging from 4.4 ± 2.7 μM*h in EM2s to 5.8 ± 1.7 μM*h, 16.3 ± 2.9 μM*h, and 50.2 ± 7.3 μM*h in EM1s, IMs, and PMs, respectively (P < 0.0001).","Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26660002/),h·μM,4.4,163128,DB00289,Atomoxetine
,26660002,area under the curve [AUC]0-∞,"Dose-corrected ATX systemic exposure (area under the curve [AUC]0-∞ ) varied 29.6-fold across the study cohort, ranging from 4.4 ± 2.7 μM*h in EM2s to 5.8 ± 1.7 μM*h, 16.3 ± 2.9 μM*h, and 50.2 ± 7.3 μM*h in EM1s, IMs, and PMs, respectively (P < 0.0001).","Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26660002/),h·μM,5.8,163129,DB00289,Atomoxetine
,26660002,area under the curve [AUC]0-∞,"Dose-corrected ATX systemic exposure (area under the curve [AUC]0-∞ ) varied 29.6-fold across the study cohort, ranging from 4.4 ± 2.7 μM*h in EM2s to 5.8 ± 1.7 μM*h, 16.3 ± 2.9 μM*h, and 50.2 ± 7.3 μM*h in EM1s, IMs, and PMs, respectively (P < 0.0001).","Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26660002/),h·μM,16.3,163130,DB00289,Atomoxetine
,26660002,area under the curve [AUC]0-∞,"Dose-corrected ATX systemic exposure (area under the curve [AUC]0-∞ ) varied 29.6-fold across the study cohort, ranging from 4.4 ± 2.7 μM*h in EM2s to 5.8 ± 1.7 μM*h, 16.3 ± 2.9 μM*h, and 50.2 ± 7.3 μM*h in EM1s, IMs, and PMs, respectively (P < 0.0001).","Single dose, CYP2D6 genotype-stratified pharmacokinetic study of atomoxetine in children with ADHD. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26660002/),h·μM,50.2,163131,DB00289,Atomoxetine
,12485957,Fecal excretion,"Fecal excretion, 32% of the total dose in the rat and 42% in the dog, appears to be due to biliary elimination and not due to unabsorbed dose.","Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485957/),%,32,165941,DB00289,Atomoxetine
,12485957,Fecal excretion,"Fecal excretion, 32% of the total dose in the rat and 42% in the dog, appears to be due to biliary elimination and not due to unabsorbed dose.","Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485957/),%,42,165942,DB00289,Atomoxetine
,12485957,F,"In the rat, low oral bioavailability was observed (F = 4%) compared with the high oral bioavailability in dog (F = 74%).","Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485957/),%,4,165943,DB00289,Atomoxetine
,12485957,F,"In the rat, low oral bioavailability was observed (F = 4%) compared with the high oral bioavailability in dog (F = 74%).","Disposition and metabolic fate of atomoxetine hydrochloride: pharmacokinetics, metabolism, and excretion in the Fischer 344 rat and beagle dog. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12485957/),%,74,165944,DB00289,Atomoxetine
,12621383,area under the concentration-time curve from time 0 to infinity,"The systemic clearance of atomoxetine was significantly reduced in those with hepatic impairment compared with controls, thereby resulting in increased exposure (area under the concentration-time curve from time 0 to infinity, 1.58 versus 0.85 microg.",Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621383/),μg,1.58,186169,DB00289,Atomoxetine
,12621383,area under the concentration-time curve from time 0 to infinity,"The systemic clearance of atomoxetine was significantly reduced in those with hepatic impairment compared with controls, thereby resulting in increased exposure (area under the concentration-time curve from time 0 to infinity, 1.58 versus 0.85 microg.",Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621383/),μg,0.85,186170,DB00289,Atomoxetine
,12621383,plasma protein binding,"Mean atomoxetine plasma protein binding was lower in patients with hepatic impairment compared with controls (96.5% versus 98.7%, P =.0008).",Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621383/),%,96.5,186171,DB00289,Atomoxetine
,12621383,plasma protein binding,"Mean atomoxetine plasma protein binding was lower in patients with hepatic impairment compared with controls (96.5% versus 98.7%, P =.0008).",Effect of hepatic impairment on the pharmacokinetics of atomoxetine and its metabolites. ,CLu-Q24,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12621383/),%,98.7,186172,DB00289,Atomoxetine
,26011686,unbound plasma drug IC50 (IC50U ),"The unbound plasma drug IC50 (IC50U ) based on plasma DHPG was 0.973 nM for duloxetine, 0.136 nM for atomoxetine, and 0.041 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,0.973,209164,DB00289,Atomoxetine
,26011686,unbound plasma drug IC50 (IC50U ),"The unbound plasma drug IC50 (IC50U ) based on plasma DHPG was 0.973 nM for duloxetine, 0.136 nM for atomoxetine, and 0.041 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,0.136,209165,DB00289,Atomoxetine
,26011686,unbound plasma drug IC50 (IC50U ),"The unbound plasma drug IC50 (IC50U ) based on plasma DHPG was 0.973 nM for duloxetine, 0.136 nM for atomoxetine, and 0.041 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,0.041,209166,DB00289,Atomoxetine
,26011686,Imax,"The baseline CSF DHPG concentration (1850-2260 ng/mL) was similar for the 3 drugs, but unlike plasma DHPG, the Imax for DHPG was 38% for duloxetine, 53% for atomoxetine, and75% for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),%,38,209167,DB00289,Atomoxetine
,26011686,Imax,"The baseline CSF DHPG concentration (1850-2260 ng/mL) was similar for the 3 drugs, but unlike plasma DHPG, the Imax for DHPG was 38% for duloxetine, 53% for atomoxetine, and75% for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),%,53,209168,DB00289,Atomoxetine
,26011686,Imax,"The baseline CSF DHPG concentration (1850-2260 ng/mL) was similar for the 3 drugs, but unlike plasma DHPG, the Imax for DHPG was 38% for duloxetine, 53% for atomoxetine, and75% for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),%,75,209169,DB00289,Atomoxetine
,26011686,IC50U,"The IC50U based on CSF DHPG was 2.72 nM for atomoxetine, 1.22 nM for duloxetine, and 0.794 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,2.72,209170,DB00289,Atomoxetine
,26011686,IC50U,"The IC50U based on CSF DHPG was 2.72 nM for atomoxetine, 1.22 nM for duloxetine, and 0.794 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,1.22,209171,DB00289,Atomoxetine
,26011686,IC50U,"The IC50U based on CSF DHPG was 2.72 nM for atomoxetine, 1.22 nM for duloxetine, and 0.794 nM for edivoxetine.","Pharmacodynamics of norepinephrine reuptake inhibition: Modeling the peripheral and central effects of atomoxetine, duloxetine, and edivoxetine on the biomarker 3,4-dihydroxyphenylglycol in humans. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26011686/),nM,0.794,209172,DB00289,Atomoxetine
,22237133,flow rate of the mobile phase,"The flow rate of the mobile phase was 250μL/min and the retention times of 4-HAT, N-DAT and internal standard (IS, metoprolol) were 0.9, 1.0 and 1.0min, respectively.",Determination of atomoxetine metabolites in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22237133/),[μl] / [min],250,222850,DB00289,Atomoxetine
,22237133,retention times,"The flow rate of the mobile phase was 250μL/min and the retention times of 4-HAT, N-DAT and internal standard (IS, metoprolol) were 0.9, 1.0 and 1.0min, respectively.",Determination of atomoxetine metabolites in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22237133/),min,0.9,222851,DB00289,Atomoxetine
,22237133,retention times,"The flow rate of the mobile phase was 250μL/min and the retention times of 4-HAT, N-DAT and internal standard (IS, metoprolol) were 0.9, 1.0 and 1.0min, respectively.",Determination of atomoxetine metabolites in human plasma by liquid chromatography/tandem mass spectrometry and its application to a pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22237133/),min,1.0,222852,DB00289,Atomoxetine
,17196891,Cmax,"The observed mean+/-S.D. pharmacokinetic parameters Cmax, Tmax and AUC(0-t) were 0.40+/-0.06 microg/ml, 3.40+/-0.42 h and 1.34+/-0.52 microg h/ml, respectively.",A new high performance liquid chromatographic method for quantification of atomoxetine in human plasma and its application for pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17196891/),[μg] / [ml],0.40,260570,DB00289,Atomoxetine
,17196891,Tmax,"The observed mean+/-S.D. pharmacokinetic parameters Cmax, Tmax and AUC(0-t) were 0.40+/-0.06 microg/ml, 3.40+/-0.42 h and 1.34+/-0.52 microg h/ml, respectively.",A new high performance liquid chromatographic method for quantification of atomoxetine in human plasma and its application for pharmacokinetic study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17196891/),h,3.40,260571,DB00289,Atomoxetine
,17196891,AUC(0-t),"The observed mean+/-S.D. pharmacokinetic parameters Cmax, Tmax and AUC(0-t) were 0.40+/-0.06 microg/ml, 3.40+/-0.42 h and 1.34+/-0.52 microg h/ml, respectively.",A new high performance liquid chromatographic method for quantification of atomoxetine in human plasma and its application for pharmacokinetic study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17196891/),[h·μg] / [ml],1.34,260572,DB00289,Atomoxetine
